April 27, 2017
Adults with obesity assigned combination phentermine and lorcaserin therapy for 12 weeks saw greater weight loss compared with either agent alone, without an increase in potentially serotonergic adverse events, according to findings from a pilot safety study published in Obesity.
“In clinical studies, coadministration of serotonergic and noradrenergic drugs has led to additive weight loss,” Steven R. Smith, MD, chief scientific officer of Florida Hospital Research Services and scientific director at the Translational Research Institute for Metabolism and Diabetes at the Sanford Burnham Prebys Medical Discovery Institute, and colleagues wrote. “However, phentermine may be associated with increased serotonergic activity. Lorcaserin is a serotonergic agent; therefore, coadministration with phentermine could theoretically result in serotonergic events, adversely impacting safety.”